What is InnoSkel?
InnoSkel is a pioneering platform biotechnology company dedicated to the development of novel therapies for rare skeletal diseases. By leveraging advanced biotechnological approaches, InnoSkel aims to address unmet medical needs in a patient population often overlooked by mainstream pharmaceutical development. The company's focus on rare diseases positions it within a specialized but critical segment of the healthcare industry, where innovative scientific breakthroughs can have a profound impact.
How much funding has InnoSkel raised?
InnoSkel has raised a total of $24.3M across 1 funding round:
Series A
$24.3M
Series A (2020): $24.3M with participation from Vida Ventures, Région Sud Investissement, Turenne Group, and Jeito
Key Investors in InnoSkel
Vida Ventures
Vida Ventures is a next-generation life sciences investment firm focused on advancing transformative biomedical innovations. They are known for their significant capital under management and a mission to bring science to life, particularly in areas with the potential to make a meaningful difference for patients.
Région Sud Investissement
Région Sud Investissement provides capital financing and investment solutions to businesses, with a focus on growth companies and regional development. They offer a range of financing options to support business expansion and transfers.
Jeito
Jeito Capital is a global investment company with a patient benefit-driven approach, financing and accelerating the development of medical innovation. They support entrepreneurs with significant capital to build market leaders and ensure accelerated patient access to new therapies.
What's next for InnoSkel?
The substantial enterprise-level funding and recent strategic investment indicate a strong validation of InnoSkel's scientific approach and therapeutic pipeline. This capital infusion is expected to accelerate the company's research and development efforts, potentially advancing its lead candidates through clinical trials and towards regulatory approval. The backing from prominent life science investors suggests a clear pathway for InnoSkel to scale its operations and solidify its position as a leader in the rare skeletal disease therapeutic space.
See full InnoSkel company page
